H. Lundbeck Boston Consulting Group Matrix

H. Lundbeck's strategic brands are truly shining stars in their portfolio, demonstrating impressive global expansion. In 2024, these key brands experienced a significant growth acceleration of 21% CER, and this momentum continued into Q1 2025 with a remarkable 24% CER increase.

This robust performance is a testament to their strong market positions, with strategic brands now contributing between 75% and 77% of Lundbeck's total revenue. The growth is widespread, with particularly strong showings in the U.S., Europe, and International Operations, underscoring their ability to capture market share in diverse and expanding geographies.

The sustained prescription uptake and increasing market share across these major regions solidify their status as stars. This indicates a healthy and growing demand for Lundbeck's core offerings on a global scale.

H. Lundbeck's strategic brands, including Vyepti and Rexulti, are classified as Stars in the BCG Matrix due to their high market share and rapid growth. Vyepti's revenue surged by 72% CER in 2024 and continued at 62% CER in Q1 2025, capturing an all-time high U.S. market share for migraine prevention. Rexulti also demonstrated strong performance, with 16% CER growth in 2024 and 28% CER in Q1 2025, boosted by its new indication for agitation associated with Alzheimer's disease.

H. Lundbeck's established market presence in neuroscience means some of its older, well-known brands hold onto significant market share, even if the overall market isn't growing rapidly. These products are strong because doctors know them, patients are used to them, and they're readily available through established distribution channels.

This stability is crucial; these mature brands generated approximately DKK 5.6 billion in revenue for Lundbeck in 2023, contributing significantly to the company's overall financial health and providing a reliable income stream.

H. Lundbeck's established products, like Brintellix/Trintellix and the Abilify LAI franchise, are prime examples of Cash Cows. These mature offerings benefit from strong brand recognition and established market positions, ensuring consistent revenue generation. Their efficiency stems from optimized production and reduced marketing needs, leading to robust profit margins.

The financial strength derived from these Cash Cows is crucial. In 2024, Brintellix/Trintellix generated DKK 4,847 million in revenue, while the Abilify LAI franchise brought in DKK 3,504 million. This stable income stream provides Lundbeck with the necessary capital to invest in its innovation pipeline and pursue strategic growth opportunities.

Onfi, once a key product for H. Lundbeck, has seen its market position significantly weaken. Since October 2018, the introduction of generic versions has led to substantial sales decline, pushing Onfi into a low market share category within Lundbeck's portfolio. This erosion directly impacts its contribution to overall revenue, reflecting a challenging market dynamic for the drug.

Products classified as Dogs in H. Lundbeck's portfolio, like Ebixa and Onfi, are characterized by low market share in low-growth markets. These products typically face intense competition, often from generics, leading to declining revenues and limited future potential.

The strategic implication for these 'Dog' products is often a decision to minimize investment or consider divestment. This allows the company to reallocate resources towards more promising Stars or Question Marks, thereby optimizing its overall portfolio performance.

For example, Ebixa's sales have been negatively impacted by China's Value-Based Procurement policies since late 2020, a clear indicator of a challenging market environment for low-share products. Similarly, Onfi experienced significant sales decline after generic entries in October 2018.

Azilect, a Parkinson's drug, also falls into this category due to substantial generic erosion and operating in a mature, low-growth segment, with generic penetration increasing as of early 2024.

Lu AG09222, an investigational monoclonal antibody targeting PACAP, is currently in Phase IIb trials for migraine prevention, positioning it as a potential disruptor in the expanding migraine market. Its novel mechanism of action offers a new therapeutic avenue, but as an investigational product, its market share is presently negligible.

H. Lundbeck's investment in Lu AG09222 reflects a strategic move to capture a portion of the migraine market, which was valued at approximately $7.9 billion globally in 2023 and is projected to grow. Success in late-stage clinical trials and subsequent market entry will be crucial for establishing a significant market presence for this product.

Question Marks in H. Lundbeck's portfolio are assets with high growth potential but currently low market share, demanding significant investment to achieve success. These products are typically in the early to mid-stages of clinical development, making their future market position uncertain.

Amlenetug (Lu AF82422) for Multiple System Atrophy and Lu AG09222 for migraine prevention exemplify this category, requiring substantial financial commitment for further development and market entry.

The success of these Question Marks is contingent upon positive clinical trial results and regulatory approvals, which will determine if they transition into Stars or remain underdeveloped.

H. Lundbeck's strategic allocation of resources to these Question Marks reflects a calculated approach to building its future revenue streams.